Latest1 information on COVID-19
©2022 Stanford Medicine
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
Not Recruiting
Trial ID: NCT00445146
Purpose
The main objective of this study is to observe the long-term safety of elvitegravir (EVG)
boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in
participants who have completed a prior EVG+RTV treatment study.
Official Title
A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects
Stanford Investigator(s)
Philip Grant
Assistant Professor of Medicine (Infectious Diseases)
Eligibility
Inclusion Criteria:
- Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.
- Males and females of childbearing potential must agree to utilize effective
contraception methods.
- Ability to understand and sign a written informed consent form.
Exclusion Criteria:
- Females who are pregnant or breastfeeding.
- Participation in any other clinical trial without prior approval from the Sponsor.
- Any other clinical condition or prior therapy that, in the opinion of the
investigator, would make the subject unsuitable for the study.
- Subjects receiving ongoing therapy with contraindicated drugs.
Intervention(s):
drug: EVG
drug: RTV
drug: ARV regimen
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Debbie Slamowitz
(650) 723-2804